At the Annual General Meeting held on 27 April 2017, the board was authorized to decide on the acquisition and sale of the company’s own shares up and until the forthcoming Annual General Meeting. The shares acquired may not exceed 10 per cent of the total number of outstanding Biotage shares at any time. The purpose of the repurchase program is to give the board a wider freedom of action in the work with the company’s capital structure and thereby improve shareholder value. Purchase of shares will take place on the NASDAQ OMX Stockholm at a price within the price interval at any time recorded.
The total number of outstanding shares in Biotage amounts to 64.714.447. As of the 28th of April 2017 Biotage do not own any Biotage shares.